A Study to Evaluate the Safety and Efficacy of CBD-OS in Participants With DEE
← catalyst calendarNCT07723976 · readout in 1,112 d
Sponsored by Jazz Pharmaceuticals (industry) · JAZZ — their whole pipeline →. With Jazz Pharmaceuticals Research UK Limited.
Phase
Phase 3
Status
Not yet recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
120estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-10-30 | estimated | When the study began enrolling |
| Primary completion | 2029-09-04 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-09-04 | estimated | The whole study's end, after follow-up |
| First posted | 2026-07-23 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Developmental and Epileptic Encephalopathy (DEE)
Interventions
- Drug: CBD-OS — also filed as JZP926-OS
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFChange in Countable Motor Seizure Frequency Per 28 Days
measured Baseline up to 6 weeks of double-blind treatment period
Permalink · JAZZ's whole pipeline · Catalyst calendar · Every registered study · What changed